• Clinicians must assess whether the patient has the capacity to make valid treatment choices in accordance with the principles of the Mental Capacity Act.
• Acetylcholinesterase inhibitors are the mainstay of dementia treatment; however, significant interactions with neuromuscular blocking agents can occur.
• Surgical patients with dementia are more likely to develop postoperative complications, especially delirium.
• A multimodal approach (including staff education, minimizing the use of sedative drugs, and effective multimodal analgesia) may reduce the incidence of complications
The most recent estimate suggests that up to 850 000 people in the UK are currently living with dementia, and this number is set to increase to 1 million by 2025. 1 As the incidence of dementia approximately doubles for every 5 yr increase in age, and older patients are increasingly presented for anaesthesia and surgery, anaesthetists are likely to encounter this group of patients with their unique set of challenging problems 2 in everyday clinical practice. This article will outline some of the diagnostic and clinical features which characterize dementia, and the implications this condition and its treatment can have when planning perioperative care.
Dementia or major neurocognitive disorder?
Dementia is a slowly progressive loss of cognitive abilities, which exceeds the normal age-related decline in brain efficiency and is therefore classified as a disease. While dementia is still considered acceptable nomenclature, and will be used throughout this article, the most recent American Psychiatric Association Diagnostic and Statistical Manual (DSM-V, 2013) has now grouped it with delirium and amnestic disorder under the encompassing term of neurocognitive disorder (NCD). 3 A diagnosis requires a decline in cognitive function across domains including attention, executive function, memory, language, and perception, which is not attributable to another mental disorder such as depression, delirium, or schizophrenia. It can be further subdivided into major or minor subtypes according to its functional impact, and test performance on formal examination of cognition. Dementia, the major subtype, requires both memory loss and loss of social competence for at least 6 months along with one or more symptoms of loss of executive function, apraxia, aphasia, or agnosia. Mild cognitive impairment (also termed pre-dementia), the minor subtype, requires the patient to show evidence of modest cognitive decline without interference with everyday activities, that is, patients can still perform complex activities such as managing medications, but this requires greater effort. DSM-V classification furthermore requires the physician to specify the likely aetiology when a diagnosis of major NCD is made.
The three most common types of dementia in the UK are Alzheimer's disease, vascular dementia, and dementia with Lewy bodies. Although different aetiologies tend to present with different constellations of symptoms and behavioural patterns (Table 1) , they may co-exist (mixed dementia) and therefore be difficult to differentiate clinically. Definitive diagnosis is usually confirmed at post-mortem. Knowing the type of dementia is important as it influences the postoperative management of complications such as delirium in this group of patients.
What are the perioperative issues?

Consent/capacity
The principles of obtaining informed consent require the patient to be able to understand and retain information relevant to the procedure being consented to. This includes its risks and benefits, weighing up the consequences of various options (such as declining consent) and making a non-coerced decision. All these steps may present difficulties to a greater or lesser degree for the patient with dementia. Furthermore, these patients' cognitive state may deteriorate transiently in the setting of acute illness or trauma such that even those with capacity under normal circumstances may temporarily lack it in emergency situations. Where lucidity fluctuates, consent may be given in a lucid period whereby the patient consents to treatment even should they subsequently refuse it while delirious (a 'Ulysses pact').
All perioperative care providers should be aware that advance directives and living wills are becoming more common, particularly within this patient group. The patient's next of kin should be consulted if there is any doubt as to whether or not one exists, as specific medical interventions such as cardiopulmonary resuscitation or supplementary nutrition may have been explicitly refused in advance. The Mental Capacity Act 2005 in England and Wales and Adults with Incapacity 2000 (Scotland) Act make provision for the appointment of a welfare attorney who can consent to treatment on a patient's behalf. No such provision exists in Northern Irish law. It is good practice to discuss any treatment decisions with relatives of the patient, and although their views have no status in law, this is important in assessing the patient's best interests, and may be a requirement of the Human Rights Act, according to the BMA. In England and Wales, if there are no relatives or friends to speak with, the Mental Capacity Act requires that an Independent Mental Capacity Advocate be consulted about all serious medical treatment decisions.
While patients' autonomy should be maximized, if there is doubt as to a patient's capacity and no welfare attorney is appointed, the opinion of an experienced psychiatrist may be of benefit if time permits. This may be particularly relevant in the context of refusing urgent but not time-critical surgery judged to be in the patient's best interest. In an emergency situation where there is insufficient time to make a thorough assessment of capacity, but the patient requires immediate medical intervention, the doctrine of emergency (or implied consent) will apply. In such circumstances, consent to treatment to preserve life, prevent disability, or avoid significant deterioration in the patient's health is presumed, and the clinician must act in what they judge to be the patient's best interests. It is advisable to contact the next of kin as soon as is practicable, to document fully the reasons for proceeding with treatment without consent, and if possible to have a senior colleague confirm and document their independent assessment of the situation.
Preoperative risk assessment and management
Coexisting medical conditions such as cardiovascular disease, chronic obstructive pulmonary disease, and renal impairment are over-represented in patients with dementia; unsurprisingly, the higher the number of comorbidities, the higher the incidence of postoperative adverse events. In a recent large-scale retrospective analysis, surgical patients with dementia had higher postoperative complication rates (urinary tract infection, pneumonia, septicaemia, stroke, and acute renal failure). 4 Furthermore, while cognitive impairment is not currently included in most definitions of frailty, and not all patients with dementia become frail, the two conditions are closely associated. 5 The risk of polypharmacy and potential for drug interactions is also increased. A thorough preoperative assessment, with particular attention to functional status (including ambulation and activities of daily living), nutritional status (and risk of pressure sores), and social issues including alcohol intake and care arrangements at home, is, accordingly, essential. Any surgery in patients with dementia needs to realistically improve their quality of life and decisions should be multidisciplinary. At the end of 
Potential for drug interactions
Specific dementia treatment largely comprises the use of acetylcholinesterase inhibitors. The decrease in central cholinergic neurones in Alzheimer's disease patients is suggestive of a link between cognitive deficits and loss of cholinergic input. 6 Indeed one of the earliest anti-dementia treatments was tacrine, which had previously been used in anaesthesia for reversal of neuromuscular block and to prolong succinylcholine paralysis. Newer-generation anticholinesterases such as donepezil and rivastigmine used in the treatment of dementia retain this capacity to both prolong the effect of depolarizing and decrease or reverse the effect of non-depolarizing neuromuscular blockers. 7, 8 Available guidelines suggest stopping these acetylcholinesterase inhibitors before elective surgery. 9 Both galantamine and rivastigmine have short half-lives (7-8 and 3-4 h, respectively) and can be discontinued the day before surgery. Donepezil, on the other hand, has a long half-life of 70 h and would require a washout period of 2-3 weeks. This period without treatment may however engender irreversible decline in cognitive function and there is no definitive guidance on whether this drug should be continued or discontinued before elective surgery. All temporarily discontinued anti-dementia agents should be re-introduced as soon as practicable in the postoperative period.
In situations where it is not practical to stop anticholinesterase therapy, e.g. emergency surgery, the anaesthetist should be aware of the potential for interactions and consider avoiding neuromuscular blocking agents altogether. However, if a non-depolarizing neuromuscular blocking agent is required, there are two options available. Since the reversal agent, neostigmine may be relatively ineffective (due to the pre-existing level of cholinesterase inhibition) or, worse still, prolong neuromuscular block via a Phase II-type interaction with succinylcholine, short-acting agents that are spontaneously inactivated (e.g. atracurium, cisatracurium) should be used. Alternatively, the use of sugammadex to predictably reverse rocuronium and vecuronium may be preferable. It is worth emphasizing that larger doses of all non-depolarizing neuromuscular blocking agents may be required to achieve satisfactory paralysis due to pharmacological antagonism caused by the anti-dementia drugs; hence, the latter strategy may be superior as larger doses of these drugs can be given safely in the knowledge that predictable reversal can be achieved with sugammadex. The routine use of peripheral nerve stimulators is invaluable in these circumstances. Where rapid sequence induction is required in these patients, the combination of rocuronium and reversal with sugammadex is likely to be safest as it avoids the problem of prolonged paralysis with succinylcholine.
In addition to cholinesterase inhibitors, other drugs prescribed to patients with dementia to improve cognition and alleviate behavioural symptoms may interact with anaesthetic drugs and increase the risk of perioperative complications (Table 2) . One group of medication often overlooked in these patients is the herbal remedy, Ginkgo biloba. The leaf of the ginkgo tree is used to treat memory loss but may interfere with platelet function leading to impaired haemostasis. It is recommended that all herbal medicines are discontinued 2 weeks before surgery.
Sensitivity to anaesthetic agents
Dementia may be associated with an increase in slow wave (δ and θ) and a decrease in fast wave (α and β) EEG activity. This translates to a lower bispectral index (BIS) score in the awake state compared with normal patients. In a small randomized controlled trial of total i.v. anaesthesia, patients with dementia required less propofol for induction and the eye opening time was longer compared with controls. 10 The investigators concluded that target BIS value for adequate anaesthesia is inappropriate for patients with cognitive impairment. However, a more recent retrospective case-control analysis investigating the sensitivity to volatile anaesthetics in patients with dementia found no difference in sensitivity. 11 Therefore, the issue of whether patients with dementia are more sensitive to anaesthetic agents remains unanswered, although in the context of a mainly elderly and potentially frail population, the consequences of excessively deep anaesthesia are likely to be significantly amplified and hence judicious reduction in anaesthetic dosages and the use of depth of anaesthesia monitoring is warranted.
Postoperative issues
Delirium
A major early postoperative concern in patients with dementia is the development of delirium. Delirium is an acute confusional state characterized by inattention, abnormal level of consciousness, thought disorganization, and a fluctuating time-course. Compared with normal hospitalized older patients, patients Potentiates effects of anaesthetics and opioids with dementia are more at risk of delirium (59 vs 13% in controls in one study). 12 Delirium also increases the risk of postoperative complications such as falls and pneumonia, prolongs hospitalization, and increases mortality (doubling the risk within 1 yr). Furthermore, an episode of delirium may accelerate the rate of cognitive deterioration up to 2 times in long-term follow-up. 13 Strategies to minimize the precipitation of delirium include avoiding the use of benzodiazepines and drugs with anticholinergic side-effects (e.g. cyclizine) perioperatively, using enhanced recovery principles to maximize an early return to patients' home and routines, and prophylaxis with antipsychotic medication. The use of BIS-guided anaesthesia has resulted in significantly less delirium in the immediate postoperative period in an elderly population, with a number needed to treat (NNT) of 12.
14 Effective multimodal analgesia cannot be overemphasized as both uncontrolled pain and over-reliance on opioid analgesia may contribute to delirium. Furthermore, the use of a multicomponent programme using evidence-based, non-pharmacological methods targeting delirium-promoting issues such as disorientation, immobility, poor sleep, visual and hearing impairment, and dehydration has been shown to be of some benefit in preventing delirium and may be cost-effective. 15 Although delirium is common in this vulnerable patient group, it tends to be under-recognized; especially the hypoactive subtype. To increase detection rates, instruments such as the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) or the 4AT screening test should be performed regularly during the postoperative period. CAM-ICU will be familiar to most anaesthetists and is widely available on the Internet, while the 4AT is a rapid assessment of alertness, attention, cognition, and fluctuation in mental state which is also freely available online.
If preventive measures fail to prevent delirium, behavioural approaches should be used first, e.g. repeated orientation, maximization of family support, and addressing sensory needs (such as glasses and hearing aids). Small doses of haloperidol are still the pharmacological treatment of choice in this patient group: 0.5-1 mg orally hourly (maximum of 5 mg in 24 h) or 2 hourly i. m. Alternative agents include risperidone 0.25 mg orally or olanzapine 2.5-5 mg orally 2 hourly up to a maximum of 10 mg in 24 h. It is important to stress that in patients with Lewy body dementia or Parkinson's disease dementia, both haloperidol and risperidone are contraindicated as severe reactions, e.g. autonomic instability, drowsiness, and neuroleptic malignant syndrome, may ensue. In such patients, lorazepam (0.5-1 mg orally or i.m. 1-2 hourly) is the agent of choice.
Pain assessment and management
The assessment of pain in the patient with dementia may be complicated by communication difficulties related to dementia or to visual and hearing impairments, and also age-related changes in physiology. Studies have shown that patients with cognitive impairment receive less analgesia for similar operative procedures, which may be partly related to their decreased ability to communicate when in pain or request additional analgesia. 16 This view is supported by functional magnetic resonance imaging studies on pain-related brain activity which demonstrate that pain perception and processing are not diminished in patients with dementia. 17 Therefore, early identification of pain is paramount to avoid the consequences of under-treatment.
Dementia is not an all-or-nothing phenomenon and hence a range of tools will be needed to appropriately assess pain in patients with different levels of cognitive impairment.
• Mild to moderate cognitive impairment: verbal rating scale (e.g. 'is your pain mild, moderate, or severe?') is more effective than the numeric scale.
• Severe cognitive impairment: observational tools, e.g. the Abbey Pain Scale, which is widely available online, allows the assessor to score a range of behavioural and physiological parameters in order to rate the pain as absent, mild, moderate, or severe.
In situations where assessment is difficult, an empirical trial of analgesia may be necessary to ascertain whether the patient is in discomfort. Furthermore, it is important to specifically assess dynamic pain relief, or the patients' ability to move and/or cough, as a marker of adequate analgesia. However, patients with dementia may not be able to perform these manoeuvres to command and therefore, this assessment may require a member of staff to observe the patient for some time.
When analgesia is prescribed for this group of patients, regular rather than as required should be the norm. Although opioid analgesia should not be avoided where it is indicated, the potential for adverse effects including promotion of delirium is amplified and the 'start low and go slow' approach is advocated. Patient-controlled analgesia is unlikely to be utilized effectively due to poor understanding; therefore, i.v. low-dose fentanyl/alfentanil infusions, transdermal fentanyl patches, or oral controlled-release preparations (if an oral route is available) with breakthrough doses are preferable. The use of regional and local anaesthesia, including the placement of perineural catheters, should always be considered as a means of reducing reliance on opioid drugs and is generally well tolerated. Regular review of analgesia requirements in this patient group is particularly important to minimize adverse effects.
Does anaesthesia/surgery cause or accelerate the course of dementia?
While much remains to be elucidated, it seems clear that the long-term effect of anaesthesia and surgery on the brain is not entirely benign. Laboratory and animal studies have demonstrated that anaesthetic agents ( primarily, but not uniquely, inhaled volatiles) may be neurotoxic by facilitating polymerization of amyloid β (Aβ) peptide monomers into larger oligomers, a key step in the formation of the amyloid plaques seen in Alzheimer's disease. The molecular size of the anaesthetic agent has also been shown by nuclear magnetic resonance spectroscopy studies to influence the degree of oligomerization with desflurane causing the least among the inhaled agents and minimal effects with the i.v. agent, propofol.
18 This is further compounded by the contribution of surgical stress and the proinflammatory state generated as a result of major surgery, with potential roles for stress hormones such as cortisol and proinflammatory cytokines such as IL6 in promoting cognitive impairment. A meta-analysis from 2011 concluded that the number of high-quality studies published was insufficient to determine definitely whether there is a relationship between anaesthesia/ surgery exposure and Alzheimer's disease. 19 However, two large retrospective studies published subsequently have both found an increased incidence of dementia after anaesthesia and surgery. 20 It might seem reasonable, nevertheless, in the light of the potential role of anaesthetic drugs in promoting postoperative cognitive impairment, to limit exposure to such agents in this population by using regional anaesthesia techniques if feasible. In situations where general anaesthesia is unavoidable, minimizing the dose and duration of exposure would appear sensible. However, robust evidence for these recommendations remains to be fully established.
Conclusions
As increasing numbers of elderly patients with dementia or mild cognitive impairment are likely to present for surgery, it is imperative that anaesthetists are aware of the potential pitfalls in delivering safe anaesthesia to this neurologically vulnerable patient group. Special consideration needs to be given to issues of consent and capacity, to the potential impact of anaesthetic drugs, and specifically, the interaction between neuromuscular blocking agents and anti-dementia drugs. Efforts to reduce the incidence of postoperative delirium include avoiding benzodiazepines and anticholinergic drugs, titrating the dose of both volatile and i.v. anaesthetic agents, and ensuring effective multimodal postoperative analgesia. Ongoing research into the link between anaesthesia, surgery, and postoperative cognitive decline may yet shed further light on strategies to protect the brain in the perioperative period.
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